In the near future it may be possible to treat PCOS and OHSS by inhibiting the expression and function of MSTN in the ovary, but in the meantime it is important to note that inhibiting MSTN may cause increased muscle content, myofibrillar hyperplasia and decreased osteoclast numbers. This evidence concerns the gene MSTN and ovarian hyperstimulation syndrome.